Genscript Biotech Corp (1548.HK) stock: key figures, P/E, revenue and dividend
Health Care · China · ISIN KYG3825B1059
Genscript Biotech Corp financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 594.00 m USD | 959.00 m USD |
| Gross profit | 272.00 m USD | 553.00 m USD |
| EBIT | -108.00 m USD | 265.00 m USD |
| Net income | 2.96 bn USD | -532.00 m USD |
| Diluted EPS – continuing operations | 1.39 USD | -0.25 USD |
Full history since 2012, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Genscript Biotech Corp
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally. It operates through Life Science Services and Products; Biologics Development Services; and Industrial Synthetic Biology Products segments. The Life Science Services and Products segment provide research services and products which are used in fundamental to life-science research and application. The Biologics Development Services segment which helps biopharmaceutical and biotech companies accelerate the development of therapeutic antibodies, and gene/cell therapy products with an integrated platform. The Industrial Synthetic Biology Products segment develops and produces industrial enzymes through non-pathogenic microbial strains constructed using genetic engineering. It also offers SurePAGE, a precast gel series; CytoSinct, a Nanobeads product and services; and Benz-Neburase, a genetically engineered endonuclease. In addition, the company provides automated protein and antibody purification system; automated maxi-plasmid purification; automated mini-scale purification for plasmid, protein, and antibody; eBlot and eStain, a protein transfer and staining system; eZwest Lite, an automated western blotting device; CytoSinct, a cell isolation solution; pharmacokinetics and immunogenicity ELISA kits; COVID-19 detection cPass technology kits; and GenBox, a mini electrophoresis tank. It serves antibody drug discovery; gene therapy; vaccine; in vitro diagnostics; gene editing; plant biology; and synthetic biology solutions. The company was founded in 2002 and is headquartered in Wan Chai, Hong Kong.
More stocks
- Capitaland Investment Ltd (9CI.SI)
- Allison Transmission Holdings Inc (ALSN)
- MISC Bhd (3816.KL)
- ENN Ecological Holdings Co Ltd (600803.SS)
- Bid Corporation Ltd (BID.JO)
- China Merchants Port Holdings Co Ltd (144.HK)
- Weir Group PLC (WEIR.L)
- VeriSilicon Microelectronics Shanghai Co Ltd (688521.SS)
- Federal Realty Investment Trust (FRT)
- Vietnam Prosperity Joint Stock Commercial Bank (VPB.VN)
- China Oilfield Services Ltd Class A (601808.SS)
- Full Truck Alliance Co Ltd ADR (YMM)
Not investment advice. All data without warranty, price as of 16.10.2026. Details in the risk notice.